Gain Therapeutics shares are trading higher after the company announced that the FDA has authorized the company’s Investigational New Drug application for GT-02287.

Benzinga Newsdesk www.benzinga.com Positive 94.5%

Neg 0% Neu 0% Pos 94.5%

Comments

No comments yet. Be the first!